Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma

Reuters

2025/10/31

Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma

Transcenta Holding Limited has announced that its partner, Inhibrx Biosciences, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with Fast Track and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579310166"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579310166\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579310166?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 06:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579310166","market":"us","top_or_hot":-1,"title":"Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Transcenta Holding Limited has announced that its partner, <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a>, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTranscenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-31 06:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Transcenta Holding Limited has announced that its partner, <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a>, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL9hyr32:1","article_id":"2579310166","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579310166","pubTimestamp":1761864283,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Transcenta Holding Limited has announced that its partner, Inhibrx Biosciences, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart  in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application  in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5  agonist antibody, with Fast Track and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK4139":"生物科技","INBX":"Inhibrx Biosciences","06628":"创胜集团-B"},"translate_title":"Transcenta报告Ozekibart治疗软骨肉瘤的积极2期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06628":0.9,"INBX":0.9},"content_text":"Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma\n    \n\n        Transcenta Holding Limited has announced that its partner, Inhibrx Biosciences, Inc., has reported positive topline results from the registrational ChonDRAgon Phase 2 study of ozekibart (INBRX-109) in patients with advanced or metastatic, unresectable chondrosarcoma. The study, which included 206 patients, investigated ozekibart as a single agent versus placebo. Based on these results, Inhibrx plans to submit a Biologics License Application (BLA) in 2026. Ozekibart is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, with Fast Track and orphan drug designations from the U.S. FDA for chondrosarcoma. Inhibrx is also evaluating ozekibart in combination with irinotecan-based regimens in Ewing sarcoma and colorectal cancer, with early signals supporting further exploration in these tumor types.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcenta Holding Limited published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}